All CARB-X articles
-
NewsCARB-X to support lower respiratory tract infection diagnostic by Zeteo
CARB-X has awarded Zeteo Tech, Inc. US$1M to execute a workplan for its noninvasive diagnostic platform that aims to evaluate whether exhaled breath can diagnose lower respiratory tract infections (LRTIs) in high-risk populations within critical care environments.
-
NewsCARB-X backs neonatal sepsis diagnostic platform by Quantamatrix
CARB-X has awarded QuantaMatrix Inc. US$2.85M to execute a workplan to develop its rapid diagnostic platform to detect sepsis, especially in vulnerable neonates. The test aims to deliver results within just 6 hours from very small blood samples of 1 to 2 milliliters.
-
NewsCARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
NewsCARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
NewsRapid test for UTI wins $10m Longitude Prize on AMR to transform fight against superbugs
Sysmex Astrego’s PA-100 AST System has won the $10m (£8m) Longitude Prize on AMR. The winning test provides accurate antibiotic susceptibility results in 45 minutes – compared to the 2-3 day wait patients currently face.
-
NewsCARB-X funds Visby Medical to develop a portable rapid diagnostic for gonorrhea
Visby Medical aims to improve patients’ health outcomes and increase the lifespan of the last remaining antibiotic for resistant gonorrhea.
-
NewsNovo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to $25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this ...
-
NewsResearchers developing an oral therapeutic to treat drug-resistant bacterial pneumonia
Australian researchers aim to rescue common antibiotics with a new therapeutic approach, using a drug originally developed to treat neurodegenerative disorders.